Overview

Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Status:
Suspended

Trial end date:
2019-01-01

Target enrollment:

Participant gender:

Summary

This is a two arm, open label, multi-center, Phase 2 study to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable Hepatocellular Carcinoma (HCC) or Intra Hepatic Cholangiocarcinoma (ICC) confined to the liver.

Phase:

Phase 2

Details

Lead Sponsor:

Delcath Systems Inc.

Treatments:

Melphalan